# HGH (Somatropin) Dosage Protocol Guide: Reconstitution & Research Protocols (2026)
> Medical Context Note: Somatropin (recombinant human growth hormone, rHGH) is FDA-approved for multiple indications including pediatric growth hormone deficiency, adult growth hormone deficiency, short bowel syndrome, HIV-associated wasting, and several pediatric growth disorders. Approved therapeutic use requires a valid prescription from a licensed physician. This article covers research protocols and reconstitution procedures for educational purposes.
What Is HGH (Somatropin)?
Human Growth Hormone (HGH), scientifically termed somatropin when referring to the recombinant biosynthetic form, is a 191-amino acid, 22-kDa polypeptide hormone synthesized and secreted by somatotroph cells of the anterior pituitary gland. It is one of the most studied hormones in endocrinology, with therapeutic applications spanning six decades since bovine-derived GH was first used therapeutically in the 1950s.
Modern pharmaceutical-grade somatropin is produced via recombinant DNA technology, identical in sequence to endogenous human GH. It is available from multiple manufacturers including Novo Nordisk (Norditropin), Pfizer (Genotropin), Eli Lilly (Humatrope), and several biosimilar manufacturers.
The pituitary axis:
- •Hypothalamus → releases GHRH (Growth Hormone Releasing Hormone) and somatostatin
- •GHRH stimulates pituitary somatotrophs → GH release
- •Somatostatin inhibits GH release
- •Pituitary → releases GH in pulses (highest at night, especially during deep sleep)
- •GH → stimulates liver to produce IGF-1 (Insulin-like Growth Factor-1)
- •IGF-1 → mediates most of GH's anabolic effects on muscle, bone, and other tissues
- •IGF-1 → provides negative feedback to both hypothalamus and pituitary
Reconstitution Protocol
Somatropin for research and therapeutic use is supplied as lyophilized (freeze-dried) powder. Proper reconstitution is critical for potency preservation and sterility.
Equipment Needed
- •Bacteriostatic water for injection (BAC water, 0.9% benzyl alcohol) — standard for multi-dose vials
- •Sterile water for injection — for single-use vials or when benzyl alcohol is contraindicated
- •1 mL insulin syringes (U-100, 28–31 gauge needles)
- •Alcohol prep pads
Step-by-Step Reconstitution
1. Prepare workspace: Clean surface, wash hands, swab both vial tops with alcohol
2. Temperature: Allow lyophilized vial to reach room temperature (15–20 minutes from refrigerator)
3. Add solvent:
- Draw desired BAC water volume into insulin syringe
- Insert needle through rubber stopper at an angle
- Slowly inject BAC water down the inner glass wall — NEVER directly onto the white powder cake
- Recommended volume: 1–2 mL per vial (higher volume = easier dose measurement; lower volume = more concentrated)
4. Dissolve:
- Gently swirl the vial in a circular motion — do NOT shake vigorously (foam formation indicates protein denaturation)
- Swirl for 30–60 seconds until the powder is completely dissolved
- Solution should be clear and colorless; any clouding, color, or visible particles indicates a problem
5. Store reconstituted vial: Refrigerate at 2–8°C immediately; do not freeze. Use within 21–28 days (BAC water provides antimicrobial preservation).
Common Vial Sizes and Reconstitution Reference
| Vial Size | BAC Water Added | Resulting Concentration | IU per 0.1 mL |
|---|---|---|---|
| 4 IU (1.33 mg) | 1 mL | 4 IU/mL | 0.4 IU |
| 10 IU (3.33 mg) | 1 mL | 10 IU/mL | 1.0 IU |
| 10 IU (3.33 mg) | 2 mL | 5 IU/mL | 0.5 IU |
| 12 IU (4 mg) | 1 mL | 12 IU/mL | 1.2 IU |
| 16 IU (5.33 mg) | 1.6 mL | 10 IU/mL | 1.0 IU |
IU to mg conversion: 1 mg somatropin ≈ 3.0 IU (varies slightly by manufacturer; check product insert)
Storage Requirements
Critical storage parameters:
- •Lyophilized (unreconstituted): 2–8°C (refrigerator); stable for 2–3 years at proper temperature; DO NOT FREEZE
- •Reconstituted: 2–8°C; use within 21–28 days depending on manufacturer specifications
- •Light: Protect from direct light; amber vials preferred for long-term storage
- •Freezing reconstituted product: Causes protein aggregation and loss of potency — never freeze reconstituted somatropin
Travel and temperature excursions: Short-term room temperature exposure (up to 72 hours, per most manufacturer data) does not significantly degrade potency. Extended exposure above 25°C accelerates degradation.
Dosage Protocols: Research and Approved Therapeutic Contexts
FDA-Approved Therapeutic Dosing Context
For reference, FDA-approved dosing for adult growth hormone deficiency (a licensed indication):
- •Starting dose: 0.1–0.2 mg/day (0.3–0.6 IU/day) subcutaneous
- •Titrated based on IGF-1 levels, clinical response, and tolerability
- •Maximum: 1.33 mg/day (4 IU/day) in most guidelines
- •Dose adjustments: IGF-1 should be maintained in the age-appropriate normal range
Research Protocol Dosing Ranges
Research protocols in the scientific literature have studied somatropin across a wide range of doses depending on the parameter being investigated:
| Research Application | Dose Range | Frequency | Protocol Duration |
|---|---|---|---|
| GH deficiency models | 0.1–0.3 mg/day | Daily | 6–12 months |
| Body composition research | 0.1–0.5 mg/day | Daily | 12–26 weeks |
| Metabolic parameter research | 0.2–1.0 mg/day | Daily | 8–24 weeks |
| Wound healing/repair models | 0.2–0.6 mg/day | Daily | 4–12 weeks |
| Anti-aging/IGF-1 axis | 0.1–0.3 mg/day | Daily | Long-term protocols |
| High-dose anabolic research | 1.0–4.0 mg/day | Daily | 12–26 weeks |
Administration Routes
Subcutaneous injection (preferred):
- •Site rotation: abdomen (2 inches from navel), outer thighs, upper buttocks
- •Technique: Pinch skin fold, 45-degree angle injection, 1/2 inch needle depth
- •Subcutaneous delivery produces slower absorption (Tmax ~3–5 hours) and lower but more sustained GH peaks
Intramuscular injection:
- •Higher Cmax but shorter duration than subcutaneous
- •Used in some research contexts for more acute GH pulse studies
- •Generally not preferred for routine multi-injection protocols due to injection site discomfort
Timing Protocols
Pre-sleep administration:
- •Aligns exogenous GH with the body's largest natural GH pulse (slow-wave sleep)
- •Most commonly studied timing in body composition research
- •Fasting state preferred (GH is blunted by elevated insulin)
Morning (fasted) administration:
- •Allows daytime monitoring of GH/IGF-1 kinetics
- •Used in clinical research protocols requiring daytime blood draws
Split dosing:
- •High-dose research protocols may divide total daily dose into 2 injections
- •Reduces peak side effects (edema, joint stiffness) that can occur with large single doses
IGF-1 Monitoring: The Key Research Biomarker
Because GH has a short half-life (~20–30 minutes), direct GH measurement requires timed sampling. IGF-1 is the standard surrogate biomarker for GH axis activity in research and clinical settings:
- •Baseline: Always measure IGF-1 before initiating any GH research protocol
- •During protocol: Monthly IGF-1 measurement is standard; more frequently in the first 4 weeks when titrating
- •Target range: Most research protocols target IGF-1 within the age-appropriate reference range (avoiding supraphysiological levels)
- •Interpretation: IGF-1 increases of 50–100% from baseline are common with physiological GH doses; supraphysiological IGF-1 levels signal dose reduction needs
Additional monitoring parameters:
- •Fasting glucose and HbA1c (GH induces insulin resistance)
- •Thyroid function (GH can unmask central hypothyroidism)
- •Cortisol (GH affects cortisol metabolism via 11β-HSD1 inhibition)
- •Prolactin (pituitary co-secretion consideration)
- •CBC (erythropoiesis stimulation)
Potential Research Confounds and Side Effects
Research protocols must account for known GH/IGF-1 effects:
- •Fluid retention: GH stimulates sodium retention and water retention via aldosterone and direct tubular effects; can cause peripheral edema and carpal tunnel-like symptoms
- •Insulin resistance: GH antagonizes insulin action in adipose tissue and liver; blood glucose monitoring is mandatory
- •Joint and muscle pain: Common at research doses; often resolves with dose reduction or time
- •Hypothyroidism induction: GH increases conversion of T4 to rT3 (reverse T3) and may reduce free T4; thyroid monitoring is standard
- •IGF-1 elevation and cancer risk: Supraphysiological IGF-1 is associated with increased cancer risk in epidemiological studies; avoiding sustained supraphysiological levels is important in research design
Key Published Literature
1. Consensus guidelines for GH deficiency in adults. European Journal of Endocrinology, multiple updates (2007–2019).
2. Rudman D, et al. "Effects of human growth hormone in men over 60 years old." New England Journal of Medicine, 1990. — Landmark study demonstrating body composition effects; often cited in anti-aging research.
3. Gibney J, et al. "The effects of 10 years of recombinant human growth hormone in adult GH-deficient patients." Journal of Clinical Endocrinology & Metabolism, 1999.
4. Svensson J, et al. "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." Journal of Clinical Endocrinology & Metabolism, 1998.
Conclusion
Somatropin (HGH) is one of the most thoroughly studied peptide hormones with a 70-year research and therapeutic history. Proper reconstitution technique, appropriate storage, IGF-1-guided dosing, and comprehensive monitoring are essential for generating valid research data and avoiding confounds. For approved therapeutic indications, somatropin requires physician oversight and a valid prescription. All research use outside of licensed therapeutic contexts falls under research-only frameworks.
---
This article is for educational purposes only. HGH/somatropin therapy requires a valid prescription from a licensed healthcare professional. This content does not constitute medical advice.